Phase 3 LEVEL trial results
Tenax Therapeutics Stock Craters 90% After Phase 3 Trial Misses Primary Endpoint
Tenax Therapeutics closed at $13.45 on Friday. It opened Monday at $1.77. In between, the company’s only Phase 3 trial reported a treatment difference of 3.5 meters on its primary endpoint, a result so far from significance that seven Wall Street analysts cut their price targets by roughly 90% apiece within a single trading day.…
